Renovaro Inc. announced the distinguished Professor Geert Kazemier, MD, PhD, as the new Chairman of its Scientific Advisory Board. This pivotal move signifies a major leap forward in Renovaro?s quest to redefine cancer diagnosis and treatment through cutting-edge AI and immunotherapy technologies. Professor Kazemier is the Clinical Director and scientific co-director of the Cancer Center at Amsterdam University Medical Center.

The center has an extensive repository of biobank tumor material and liquid biopsies, including an extensive range of data from biomarkers, amongst others, for co-rectal, urogenital, lung, and breast cancers. Professor Kazemier has made groundbreaking contributions to oncology and surgical research. His depth of experience and trailblazing academic and clinical leadership align perfectly with Renovaro's mission.

Professor Kazemier's commitment to medical advancement positions him as an ideal leader to propel Renovaro's Scientific Advisory Board during a transformative era in oncology characterized by the integration of Artificial Intelligence. Under Professor Kazemier?s direction, Amsterdam University Medical Center?s Cancer Center has launched numerous pioneering research projects, substantially enriching understanding and treatment of cancer. His drive for innovation and excellence echoes Renovaro?s dedication to advancing early diagnosis, accurate response prediction, effective monitoring, and personalized therapy.

As the Chairman of the Scientific Advisory Board, Professor Kazemier is set to influence Renovaro's research and development trajectory. His leadership will prioritize novel research paths with the power to potentially transform cancer diagnosis, monitoring, and treatment processes.